Karuna Completes $42 Million Series A Financing Round to Advance Selective Muscarinic Receptor Agonist Program into Phase 2 Study

from Venture Capital Access Online: Latest Venture Capital and Private Equity News https://ift.tt/2LMfxnQ
via IFTTT